C
CLLS
Cellectis
3.240
-0.080-2.41%After Hours: 3.240 0.000 0.00%19:30 09/04 EDT
OPEN/PREV CLOSE3.105/3.120
TODAY RANGE3.010-3.180
VOL75.58K
MARKET CAP225.36M
52 WEEK RANGE2.350-5.48
AVG VOL (3M)21.67K
% TURNOVER0.10%
TURNOVER--
P/E (TTM)-4.7692
% RANGE5.45%
EPS(TTM)-0.6500
P/E(FORWARD)-3.7897
P/B5.49
BVPS0.5649
DIVIDEND--
P/S2.817
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP225.36M
SHARES OUTSTANDING72.70M
NEXT EARNINGS11/05-11/09
FREE FLOAT72.70M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·09/01 20:57
Cellectis Plans Heavy Investor Conference Schedule for Fall 2026
Seeking Alpha·08/25 20:56
Cellectis: 'Hold' On Lasme-Cel Q4 2026 Catalyst And Eti-Cel Backup Candidate
TipRanks·08/07 08:36
Barclays Sticks to Their Buy Rating for Cellectis SA (CLLS)
TipRanks·07/06 18:35
Citizens biotech analyst holds an analyst/industry conference call
TipRanks·07/02 19:25
Citizens biotech analysts hold an analyst/industry conference call
TipRanks·06/25 21:04
Cellectis Shareholders Approve Board-Backed Resolutions at June 25, 2026 Meeting
TipRanks·06/11 11:29
Cellectis Unveils Strong Early CAR-T Data for Lasme-cel and Eti-cel at EHA 2026
Seeking Alpha·06/10 19:19
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?
Seeking Alpha·06/10 09:01
Biggest stock movers Wednesday: CBRL, CLLS, SMCI, chip stocks, and more
Seeking Alpha·06/10 04:12
Cellectis wins FDA RMAT status for leukemia CAR-T candidate lasme-cel; shares rise
TipRanks·06/09 21:09
Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
Benzinga·06/09 21:06
12 Health Care Stocks Moving In Tuesday's After-Market Session
TipRanks·06/09 20:40
Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA
Same Industry
Name/Symbol
Change%
Price